Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

The drug is now available for prescription in New Zealand but there are clouds to go along with the silver linings - such as ...

India is stepping into the billion-dollar weight-loss drug war! With Wegovy and Mounjaro already here, Biocon is quietly ...

You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt ...

The country’s Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, the UK’s official system for ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

The company is seeking regulatory approval of generic Ozempic by September from Canadian authorities, along with other ...